Hamish Ryder Chief Executive Officer, Therapeutic Innovation
Prior to appointment as CEO of Therapeutic Innovation for Cancer Research Horizons, Hamish directed Cancer Research UK (CRUK)’s Therapeutic Discovery Labs for 14 years. He led the transition of the translational strategy to a themed multi-project alliance model where industry partners and academic researchers are brought together from the earliest stages of target selection and validation.
Prior to joining Cancer Research Horizons, he held positions in biopharma companies for over 20 years, most recently as Director of Research at Almirall, Spain’s largest pharmaceutical company. He has worked across multiple therapeutic areas, leading organisations that have discovered >30 candidate drugs for regulatory development, that have so far yielded 2 marketed therapies. Hamish obtained a degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.